Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap
Gene Therapy Launch Delayed Again
Executive Summary
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
You may also be interested in...
Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.
Vertex’s ‘Slow Train To Pain’ R&D Rolls On
Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.
Bluebird Bio Withdraws Zynteglo From Germany Over Pricing
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.